# CJC-1295 Ipamorelin: Full Reference Index

> CJC-1295 ipamorelin peer-reviewed citations: 22 primary findings plus 4 recent studies. Full citation index with DOIs and PubMed URLs. All claims on this site trace to this index.

## About This Citation Index

The CJC-1295 ipamorelin literature indexed on this site spans 1998–2025, covering human Phase I/II-context trials, rat and mouse pharmacokinetic studies, bone mineral content protocols, GI motility models, sleep architecture research, secretagogue class reviews, equine doping-control methods, and FDA-approved GHRH analog data (tesamorelin) as a class-level comparator.

## Primary Research Findings

[1] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. DOI: 10.1210/jc.2006-1702 https://pubmed.ncbi.nlm.nih.gov/17018654/

[2] Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. DOI: 10.1210/en.2004-1286 https://pubmed.ncbi.nlm.nih.gov/15817669/

[3] Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. DOI: 10.1530/eje.0.1390552 https://pubmed.ncbi.nlm.nih.gov/9849822/

[4] Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. DOI: 10.1054/ghir.1999.9998 https://pubmed.ncbi.nlm.nih.gov/10373343/

[5] Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. DOI: 10.1152/ajpendo.00201.2006 https://pubmed.ncbi.nlm.nih.gov/16822960/

[6] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. DOI: 10.1016/j.ghir.2009.03.001 https://pubmed.ncbi.nlm.nih.gov/19386527/

[7] Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998;28(12):1243-1252. DOI: 10.1080/004982598238976 https://pubmed.ncbi.nlm.nih.gov/9879640/

[8] Andersen NB, Malmlöf K, Johansen PB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-272. DOI: 10.1054/ghir.2001.0239 https://pubmed.ncbi.nlm.nih.gov/11735244/

[9] Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. DOI: 10.1677/joe.0.1650569 https://pubmed.ncbi.nlm.nih.gov/10828840/

[10] Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116. DOI: 10.1124/jpet.108.149211 https://pubmed.ncbi.nlm.nih.gov/19289567/

[11] Ho KY, Veldhuis JD, Johnson ML, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 1988;81(4):968-975. DOI: 10.1172/JCI113450 https://pubmed.ncbi.nlm.nih.gov/3127426/

[12] Weikel JC, Wichniak A, Ising M, et al. Ghrelin promotes slow-wave sleep in humans. Am J Physiol Endocrinol Metab. 2003;284(2):E407-E415. DOI: 10.1152/ajpendo.00184.2002 https://pubmed.ncbi.nlm.nih.gov/12388174/

[13] Farhy LS, Veldhuis JD. Deterministic construct of amplifying actions of ghrelin on pulsatile growth hormone secretion. Am J Physiol Regul Integr Comp Physiol. 2005;288(5):R1649-R1663. DOI: 10.1152/ajpregu.00451.2004 https://pubmed.ncbi.nlm.nih.gov/15718392/

[14] Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. DOI: 10.1210/jcem.81.12.8954023 https://pubmed.ncbi.nlm.nih.gov/8954023/

[15] Sigalos JT, Pastuszak AW, Allison A, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017;11(6):1752-1757. DOI: 10.1177/1557988317718662 https://pubmed.ncbi.nlm.nih.gov/28830317/

[16] Memdouh S, Gavrilović I, Ng K, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(7):1233-1247. DOI: 10.1002/dta.3183 https://pubmed.ncbi.nlm.nih.gov/34665524/

[17] Smith RG, Thorner MO. Growth Hormone Secretagogues as Potential Therapeutic Agents to Restore Growth Hormone Secretion in Older Subjects to Those Observed in Young Adults. J Gerontol A Biol Sci Med Sci. 2023;78(6):975-983. DOI: 10.1093/gerona/glad022 https://pmc.ncbi.nlm.nih.gov/articles/PMC10272984/

[18] Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-247. DOI: 10.1345/aph.1Q629 https://pubmed.ncbi.nlm.nih.gov/22298602/

[19] Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-138. DOI: 10.1006/bbrc.2000.4065 https://pubmed.ncbi.nlm.nih.gov/11162489/

[20] Cappola AR, Auchus RJ, El-Hajj Fuleihan G, et al. Hormones and Aging: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 2023;108(8):1835-1874. DOI: 10.1210/clinem/dgad225 https://pmc.ncbi.nlm.nih.gov/articles/PMC11491666/

[21] Tausendfreund O, Bidlingmaier M, Martini S, et al. Growth hormone treatment in aged patients with comorbidities: A systematic review. Growth Horm IGF Res. 2024;75:101584. DOI: 10.1016/j.ghir.2024.101584 https://pubmed.ncbi.nlm.nih.gov/38489867/

[22] Timms M, Ganio K, Forbes G, Bailey S, Steel R. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019;11(4):593-601. DOI: 10.1002/dta.2554 https://pubmed.ncbi.nlm.nih.gov/30489688/

---

Twenty-two studies across six species, indexed as a folk-almanac of the CJC-1295 ipamorelin literature — no clinic behind the cordel, no vendor behind the broadside.